[6-K] Haleon plc Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc reports its total issued share capital and voting rights as of 30 September 2025. The company has 8,952,353,648 ordinary shares of £0.01 each, of which 44,400,783 are held in treasury, leaving 8,907,952,865 ordinary shares with voting rights. Shareholders and others with notification obligations should use 8,907,952,865 as the denominator when assessing disclosure thresholds under the FCA's Transparency Rules. The filing provides a contact for notifiable interests (company.secretary@haleon.com) and a brief company description of Haleon’s consumer health business and major brands.

Positive

• Exact issued share count provided: 8,952,353,648 ordinary shares reported
• Clear voting base specified for FCA notification calculations: 8,907,952,865 shares with voting rights
• Treasury shares disclosed: 44,400,783 held as treasury shares
• Contact provided for notifiable interests: company.secretary@haleon.com

Negative

• None.

Insights

Financial Analyst

TL;DR: A routine capital structure disclosure; provides exact share counts needed for ownership threshold calculations.

The report is a straightforward statement of issued shares and treasury holdings, giving the precise denominator (8,907,952,865) for FCA notification calculations. This is standard compliance reporting with no operational or financial data included. For analysts monitoring ownership changes, the filing eliminates ambiguity about the share base used for disclosure thresholds but does not affect valuation or operating performance.

Corporate Governance Expert

TL;DR: Compliance-focused disclosure that ensures market transparency about voting rights and notification obligations.

The company confirms its issued share capital and treasury shares and supplies a contact for notifiable interests. This supports regulator and investor needs for clear share-count data when assessing significant shareholdings. There are no governance changes or director-related disclosures in this filing.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	01 October 2025- “Total Voting Rights and Capital”

99.1

Haleon plc: Total Voting Rights and Capital

01 October 2025: As at 30 September 2025 the total number of shares issued by Haleon plc ("Haleon" or the "Company") is 8,952,353,648 ordinary shares of £0.01 each, of which 44,400,783 are held as treasury shares.

Therefore, the number of ordinary shares with voting rights is 8,907,952,865 and this figure should be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Notifiable interests in Haleon may be sent to: company.secretary@haleon.com

Amanda Mellor

Company Secretary

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: October 01, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

How many ordinary shares does Haleon plc (HLN) have issued?

Haleon reports 8,952,353,648 ordinary shares issued as at 30 September 2025.

What is the number of voting shares for HLN used to calculate FCA notification thresholds?

The number of ordinary shares with voting rights is 8,907,952,865.

How many treasury shares does Haleon hold?

Haleon holds 44,400,783 treasury shares.

Who should be contacted to notify a notifiable interest in Haleon?

Notifiable interests may be sent to company.secretary@haleon.com.

Does this 6-K include financial results or transaction details?

No. The filing only discloses share capital and voting rights; it contains no financial statements or transaction details.